DERM - Journey Medical Corporation
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution.
As of May 15, 2026: spot at $6.25, ATM IV 312.0%, net GEX $1.2K.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market Cap
- $141.9M
- Beta
- 1.03
- 52-Week Range
- 4.31-9.555
- CEO
- Claude Maraoui
- Employees
- 41
- IPO Date
- Nov 12, 2021
- Exchange
- NASDAQ
What DERM Looks Like to Options Traders Today
IV rank of 63.4% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($1.2K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (3.404) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The DERM overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked DERM overview questions
- What is DERM?
- DERM is the ticker symbol for Journey Medical Corporation, a listed security. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. Listed on NASDAQ. DERM is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the DERM options snapshot look like today?
- As of May 15, 2026, the DERM options snapshot shows spot at $6.25, ATM IV 312.0%, IV rank 63.4%, net GEX $1.2K, expected move 89.45%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are DERM's key statistics?
- Journey Medical Corporation (DERM) carries a market capitalization of $141.9M, beta of 1.03 relative to the broader market, 52-week range of 4.31-9.555. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does DERM belong to?
- Journey Medical Corporation operates in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare DERM's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the DERM data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).